|Articles|April 1, 2013
Anti-VEGF therapy for the treatment of glaucoma
Early reports on off-label uses for anti-VEGFs are promising
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
2
FLORetina 2025: Navigating antithrombotic therapy in wet AMD
3
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
4
FLORetina 2025: Rethinking Terson syndrome through multimodal imaging
5









































